Document is current

Article History

Received: 18 January 2021

Accepted: 26 August 2021

First Online: 9 September 2021

Declarations

:

: Not applicable.

: Not applicable.

: F. Jakobs has nothing to disclose. S. M. Wingen-Heimann has received research and travel grants from Astellas and Merck; research grants from Basilea, Gilead, and 3M; travel grants from Pfizer Inc; lecture honoraria from Astellas and Merck; and is a consultant to Basilea, Gilead, and Merck.J. Jeck has nothing to disclose.A. Kron received consultancy honoraria from Takeda, BMS, AbbVie, Novartis and MSD.O. A. Cornely is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – CECAD, EXC 2030 – 390661388 and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen, Medicines Company, Melinta, Merck/MSD, Octapharma, Pfizer, Scynexis, is a consultant to Actelion, Allecra, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini, Merck/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi, and received lecture honoraria from Al-Jazeera Pharmaceuticals, Astellas, Basilea, Gilead, Grupo Biotoscana, Merck/MSD and Pfizer.F. Kron received lecture honoraria and/or advisory board and consultancy honoraria from Pfizer Inc, MSD, Bristol Myers Squibb, Novartis, Takeda, Shire, Amgen, Janssen-Cillag, Celgene, Gilead, Bayer, Mundipharma, Riemser, Medac, Jazz Pharmaceuticals, Medipolis, Aposan, Hogan Lovells, Simon Kucher, Orphoz-McKinsey, and Aktiva Gesundheitsberatung.